C07K 14/065
Poxviridae
Official title: Poxviridae, e.g. avipoxvirus
C07K14/065 (Poxviridae) appears on 23 US grants and 39 published applications in this corpus.
Search patents in C07K- Granted patents
- 23
- Published applications
- 39
- Assignees
- 16
- Inventors
- 48
- Latest grant
- 11 Mar 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2004 | 0 | 1 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 1 |
| 2008 | 0 | 0 |
| 2009 | 0 | 1 |
| 2010 | 0 | 1 |
| 2011 | 1 | 0 |
| 2012 | 0 | 0 |
| 2013 | 2 | 6 |
| 2014 | 2 | 2 |
| 2015 | 6 | 1 |
| 2016 | 0 | 1 |
| 2017 | 2 | 3 |
| 2018 | 3 | 1 |
| 2019 | 0 | 3 |
| 2020 | 0 | 2 |
| 2021 | 1 | 3 |
| 2022 | 1 | 2 |
| 2023 | 2 | 4 |
| 2024 | 2 | 4 |
| 2025 | 1 | 0 |
| 2026 | 0 | 3 |
By publication year. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Oncolytic viruses targeting STAT311 Mar 2025US 12,246,049 B2University of Pittsburgh—Of the Commonwealth System of Higher Education
- Oncolytic viruses for modified MHC expression25 Jun 2024US 12,016,893 B2KaliVir Immunotherapeutics, Inc.
- Oncolytic viruses for modified MHC expression23 Apr 2024US 11,963,990 B2KaliVir Immunotherapeutics, Inc.
- Glycotargeting therapeutics24 Oct 2023US 11,793,882 B2Ecole Polytechnique Federale De Lausanne (Epfl)
- Compositions and methods of interferon alpha binding proteins4 Jul 2023US 11,690,895 B2Meiogen Biotechnology Corporation
- Novel capsid protein variant and use thereof6 Aug 2026US 2026/0226111 A1
- Glycotargeting therapeutics30 Apr 2026US 2026/0115300 A1Ecole Polytechnique Federale De Lausanne (Epfl)
- Self-replicating rna and use thereof23 Apr 2026US 2026/0109975 A1Nanjing GenScript Biotech Co., Ltd.
- Oncolytic viruses for modified mhc expression22 Aug 2024US 2024/0277793 A1KaliVir Immunotherapeutics, Inc.
- Oncolytic viruses for modified mhc expression22 Aug 2024US 2024/0277794 A1KaliVir Immunotherapeutics, Inc.
Most cited
By later US patents
- Glycotargeting therapeutics16US 10,046,056 B2Ecole Polytechnique Federale De Lausanne (Epfl) · 2018
- Glycotargeting therapeutics9US 10,940,209 B2Ecole Polytechnique Federale De Lausanne (Epfl) · 2021
- Immunoregulatory peptides and methods of use4US 8,450,285 B213Therapeutics, Inc. · 2013
- Recombinant proteins of parapoxvirus ovis and pharmaceutical compositions therefrom3US 8,357,363 B2AiCuris GmbH & Co. KG · 2013
- Generation of new pancreatic beta cells2US 9,133,440 B22015